Trial No.: BMS CA209-274
A Phase 3 Randomized, Double-Blind, Multi-Center Study of Adjuvant Nivolumab Versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
Trial No.: Astra Zeneca D933SC00001 NILE
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.